Eric Slosberg News Today

OnCusp Therapeutics has raised $100 million in a Series A funding round co-led by Novo Holdings, OrbiMed, and F-Prime Capital.

Press release content from PR Newswire. The AP news staff was not involved in its creation. OnCusp Therapeutics Commences Operations to Advance Innovative Oncology Therapies June 30, 2021 GMT NEW YORK, June 29, 2021 /PRNewswire/ -- OnCusp Therapeutics (or “OnCusp”), a global biopharmaceutical company focused on translating cutting-edge research assets into innovative oncology therapeutics, announced that it has officially commenced operations both in New York and Shanghai. OnCusp successful...